Evidence map›Paper›PMID 36690811›Full record

ArticleNature medicine2023

Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results.

Sham Mailankody, Jeffrey V Matous, Saurabh Chhabra, Michaela Liedtke, Surbhi Sidana, Olalekan O Oluwole, Shahbaz Malik, Rajneesh Nath, Faiz Anwer, Jose Carlos Cruz and 8 more

Erratum issued Registry-linked trialAbstract readClinical Trial, Phase I
PubMed Publisher
In one paragraph

Article in Nature medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT04093596 (A Single-Arm, Open-Label, Phase 1 Study of the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-715 to Evaluate an Anti-BCMA Allogeneic CAR T Cell Therapy With or Without Nirogacestat in Subjects With Relapsed/Refractory Multiple Myeloma), which is not on this map. Cited by 154 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
154citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04093596 phase1completednot on this map

A Single-Arm, Open-Label, Phase 1 Study of the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-715 to Evaluate an Anti-BCMA Allogeneic CAR T Cell Therapy With or Without Nirogacestat in Subjects With Relapsed/Refractory Multiple Myeloma

TypeinterventionalSponsorAllogene TherapeuticsRan2019 to 2025Enrolled73ConditionsRelapsed/Refractory Multiple MyelomaArmsALLO-715, ALLO-647, Fludarabine, Cyclophosphamide, Nirogacestat
3 · Its place in the literature

Who cites it

154 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Neurological complications of current and emerging CAR-T cell therapies.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article

94 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Sham MailankodyMyeloma Service and Cellular Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA. mailanks@mskcc.org.ORCID http://orcid.org/0000-0002-2815-9561
Jeffrey V MatousColorado Blood Cancer Institute, Denver, CO, USA.
Saurabh ChhabraDivision of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.ORCID http://orcid.org/0000-0001-9117-8696
Michaela LiedtkeDivision of Hematology, Department of Medicine, Stanford University, Stanford, CA, USA.
Surbhi SidanaDivision of Bone Marrow Transplantation and Cellular Therapy, Stanford University Hospital, Stanford, CA, USA.ORCID http://orcid.org/0000-0003-3288-7614
Olalekan O OluwoleVanderbilt University Medical Center, Nashville, TN, USA.
Shahbaz MalikBone Marrow Transplant and Cellular Therapy Program, Sarah Cannon Blood Cancer Center at St. David's South Austin Medical Center, Austin, TX, USA.
Rajneesh NathBanner MD Anderson Cancer Center, Gilbert, AZ, USA.
Faiz AnwerTaussig Cancer Institute, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH, USA.
Jose Carlos CruzTexas Transplant Institute, San Antonio, TX, USA.
Myo HtutDepartment of Hematology/HCT, City of Hope National Medical Center, Duarte, CA, USA.
Erin E KarskiAllogene Therapeutics, South San Francisco, CA, USA.
Wade LovelaceAllogene Therapeutics, South San Francisco, CA, USA.
Myles DillonAllogene Therapeutics, South San Francisco, CA, USA.
Eric ButzAllogene Therapeutics, South San Francisco, CA, USA.
Wendy YingAllogene Therapeutics, South San Francisco, CA, USA.
Arun BalakumaranAllogene Therapeutics, South San Francisco, CA, USA.
Shaji K KumarMayo Clinic, Rochester, MN, USA.ORCID http://orcid.org/0000-0001-5392-9284

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

ALLO-715 is a first-in-class, allogeneic, anti-BCMA CAR T cell therapy engineered to abrogate graft-versus-host disease and minimize CAR T rejection. We evaluated escalating doses of ALLO-715 after lymphodepletion with an anti-CD52 antibody (ALLO-647)-containing regimen in 43 patients with relapsed/refractory multiple myeloma as part A of the ongoing first-in-human phase 1 UNIVERSAL trial. Primary objectives included determination of the safety and tolerability of ALLO-715 and the safety profile of the ALLO-647-containing lymphodepletion regimen. Key secondary endpoints were response rate and duration of response. Grade ≥3 adverse events were reported in 38 (88.0%) of patients. Cytokine release syndrome was observed in 24 patients (55.8%), with 1 grade ≥3 event (2.3%) and neurotoxicity in 6 patients (14%), with no grade ≥3 events. Infections occurred in 23 patients (53.5%), with 10 (23.3%) of grade ≥3. Overall, 24 patients (55.8%) had a response. Among patients treated with 320 × 10

Indexed as

Hematopoietic Stem Cell TransplantationMultiple MyelomaCyclophosphamideHumansImmunotherapy, AdoptiveT-LymphocytesCyclophosphamide

Identifiers

PMID36690811

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.